Novartis is returning to Huntington's disease with a $1 billion upfront bet, plus another $1.9 billion in biobucks, for ...

Merus reported updated Phase 2 trial results for petosemtamab in head and neck cancer, showing 40.4% overall response rate ...

Apogee Therapeutics plans to challenge Sanofi and Regeneron's Dupixent with its lead drug APG777, an IL-13 targeting ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

FDA accepts Satsuma Pharmaceuticals' NDA resubmission for STS101 migraine drug. Hovione expands facilities in Ireland and New ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...

The FDA rejected Applied Therapeutics’ experimental treatment, govorestat, for a rare disease called classic galactosemia, ...

The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular obesity ...

The transition team for President-elect Donald Trump was still searching for its next National Institutes of Health director ...

President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

Kronos Bio announces 83% workforce reduction and CEO Norbert Bischofberger's departure, with CFO Deborah Knobelman taking ...